About CLINUVEL

Tuesday, 29 January 2013 19:37

JAMA features vitiligo study as cover story

In October 2012 we announced that observations from the CUV102 study of SCENESSE® (afamelanotide 16mg implant) in vitiligo were e-published in the journal Archives of Dermatology. Earlier this month the article was fully published in the re-named JAMA Dermatology, with case study images from CUV102 featured on the cover. You can access the abstract to this article at the JAMA's website.

Reference:

Grimes PE, et al (2013). "The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo" JAMA Dermatol. 149(1):68-73.

Latest Company Announcements

28 April 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
12 April 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
12 April 2017

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

Read More
31 January 2017

Appendix 4C - Quarterly report

Quarterly report

Read More

Quick Links